Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Subcutaneous immunoglobulin
6 evidence topics · 7 sources
Guideline recommendation for maintenance treatment
Weekly subcutaneous immunoglobulin versus placebo: relapse or withdrawal over 24 weeks
“We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the intention-to-treat set, 36 (63% [95% CI 50-74]) patients on placebo, 22 (39% [27-52]) on low-dose SCIg, and 19 (33% [22-46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Absolute risk reductions were 25% (95% CI 6-41) for low-dose versus placebo (p=0·007), 30% (12-46) for high-dose versus placebo (p=0·001), and 6% (-11 to 23) for high-dose versus low-dose (p=0·32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Facilitated subcutaneous immunoglobulin versus placebo: relapse over 6 months
“fSCIG 10% was administered at the same dose (or matching placebo volume) and interval as pre-randomization IVIG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP relapse was reduced with fSCIG 10% versus placebo (n = 6 [9.7%; 95% confidence interval 4.5%, 19.6%] vs n = 22 [31.4%; 21.8%, 43.0%], respectively; absolute difference: -21.8% [-34.5%, -7.9%], p = .0045).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events (AEs) were more frequent with fSCIG 10% (79.0% of patients) than placebo (57.1%), but severe (1.6% vs 8.6%) and serious AEs (3.2% vs 7.1%) were less common.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term facilitated subcutaneous immunoglobulin extension: relapse and tolerability
“The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“fSCIG‐related AEs ( n = 798) included infusion site reactions such as pain, redness, and pruritus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled randomized evidence for subcutaneous immunoglobulin
“Four RCTs with 360 randomised participants met our eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCIg maintenance treatment probably reduces the risk of clinically significant deterioration in disability within 12 to 24 weeks compared to placebo (RR 0.40, 95% CI 0.28 to 0.56; 3 studies, 333 participants; moderate‐certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We could not evaluate the difference between SCIg and IVIg as induction treatment in terms of rate of improvement in disability, change in grip strength, or frequency of local or systemic adverse effects, as these data were not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote